Table 1.
Baseline characteristics
| Group 1 Low stable N = 162 |
Group 2 Low increasing N = 151 |
Group 3 Elevated increasing N = 268 |
Group 4 Elevated decreasing N = 110 |
Group 5 Elevated stable N = 228 |
Total N = 919 |
|
|---|---|---|---|---|---|---|
| Age, years | 63 ±13 | 60 ±12 | 56 ± 14 | 59 ±15 | 51 ±14 | 57 ±14 |
| Female, N | 107 (66) | 98 (65) | 139 (52) | 66 (60) | 103 (45) | 513 (56) |
| Black, N | 113 (70) | 112 (74) | 173 (65) | 76 (69) | 140 (61) | 614 (67) |
| Current smoking, N | 19 (12) | 23 (15) | 59 (22) | 12 (11) | 48 (21) | 161 (18) |
| Dialysis vintage, years | 1.3 [0.6-3.1] | 1.6 [0.6-4.1] | 1.8 [0.8-4.9] | 2.3 [1.0-5.2] | 3.2 [1.4-6.7] | 2.0 [0.8-4.7] |
| Diabetes, N | 94 (58) | 78 (52) | 109 (41) | 48 (44) | 67 (29) | 396 (43) |
| Cardiovascular disease, N | 130 (80) | 115 (76) | 217 (81) | 82 (75) | 161 (71) | 705 (78) |
| Vitamin D analog use, N | 71 (44) | 80 (53) | 153 (55) | 60 (56) | 147 (65) | 511 (56) |
| Arteriovenous Access, N | 146 (90) | 143 (95) | 257 (96) | 100 (91) | 218 (96) | 864 (94) |
| MBD lab values | ||||||
| Calcium, mg/dL | 9.1 ± 1.0 | 9.1 ± 0.9 | 9.3 ± 0.9 | 9.5 ± 0.9 | 9.5 ± 1.0 | 9.3 ± 1.0 |
| Phosphorus, mg/dL | 4.8 ± 1.6 | 5.1 ± 1.5 | 5.8 ± 1.7 | 5.9 ± 2.2 | 6.6 ± 1.9 | 5.7 ± 1.9 |
| 25(OH)D, ng/mL | 14.9 [10.0-20.1] | 14.9 [9.0-24.5] | 14.9 [10.0-24.5] | 14.9 [10.0-20.1] | 16.4 [11.0-27.1] | 14.9 [10.0-24.5] |
| 1,25(OH)2D, pg/mL | 6.0 [3.0-12.1] | 6.7 [2.7-14.9] | 6.0 [2.7-12.2] | 6.0 [3.0-16.4] | 7.4 [3.3-16.4] | 6.0 [3.0-14.9] |
| PTH, pg/mL | 154 [63-304] | 188 [70-395] | 228 [96-466] | 123 [51-289] | 269 [125-604] | 194 [83-437] |
| FGF23, pg/mL | 446 [221-898] | 602 [299-1636] | 2981 [1480-6634] | 3641 [2208-7332] | 18034 [8955-32860] | 2697 [735-9897] |
| Inflammatory lab values | ||||||
| Albumin, g/dL | 3.8 ± 0.3 | 3.9 ± 0.3 | 3.9 ± 0.4 | 3.9 ± 0.3 | 4.0 ± 0.3 | 3.9 ± 0.3 |
| CRP, mg/L | 6.0 [2.5-14.9] | 5.5 [2.2-13.5] | 5.0 [2.2-10.0] | 5.0 [2.2-10.0] | 5.5 [2.5-11.0] | 5.0 [2.5-11.0] |
| IL-6, pg/ml | 2.7 [1.5-5.5] | 2.5 [1.0-5.0] | 2.7 [1.3-6.7] | 2.7 [1.3-5.5] | 2.7 [1.5-5.5] | 2.7 [1.3-5.5] |
| TNF-α, pg/ml | 30.0 [16.4-44.7] | 27.0 [16.4-40.4] | 30.0 [20.1-44.7] | 27.1 [16.4-40.4] | 27.1 [18.2-44.7] | 30.0 [18.2-44.7] |
| IFN-γ, pg/ml | 1.3 [1.0-2.2] | 1.5 [1.1-2.0] | 1.5 [1.1-2.2] | 1.6 [1.0-2.2] | 1.5 [1.1-2.2] | 1.5 [1.1-2.2] |
| High-Kt/V assignment, N | 99 (61) | 72 (48) | 138 (51) | 56 (51) | 103 (45) | 468 (51) |
| High-flux assignment, N | 85 (52) | 77 (51) | 127 (47) | 72 (65) | 99 (43) | 460 (50) |
| Residual kidney function, N | 67 (41) | 57 (37) | 103 (38) | 35 (32) | 69 (30) | 331 (36) |
| Residual urea clearance (mL/min) | 0.93 ± 1.07 | 0.82 ± 0.46 | 0.64 ± 0.41 | 0.85 ± 0.55 | 0.55 ± 0.45 | 0.73 ± 0.64 |
Data are presents as N (%), mean ± SD, or median [IQR].
Abbreviations: MBD, Mineral Bone Disorder; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; CRP, c-reactive protein; IL-6, interleukin-6, TNF-α, tumor necrosis factor-alpha; IFN-γ, interferon-gamma.